<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1288">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144386</url>
  </required_header>
  <id_info>
    <org_study_id>EBT-101-001</org_study_id>
    <nct_id>NCT05144386</nct_id>
  </id_info>
  <brief_title>Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART</brief_title>
  <official_title>A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Excision BioTherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Excision BioTherapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected&#xD;
      adults on stable antiretroviral therapy (ART).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101&#xD;
      administered IV to aviremic HIV-1 infected adults on stable ART.&#xD;
&#xD;
      On Day 1, eligible participants will receive a single IV dose of EBT-101. All participants&#xD;
      will be assessed for eligibility for an analytical treatment interruption (ATI) of their&#xD;
      background ART at Week 12. All participants will be followed through Week 48; participants&#xD;
      who undergo ATI will have more frequent study visits than non-ATI participants.&#xD;
&#xD;
      Eligible participants who are enrolled in the FIH study (EBT-101-001) will also be enrolled&#xD;
      in a separate Long Term Follow Up (LTFU) study (EBT-101-002) for safety monitoring. The&#xD;
      duration of the LTFU study will be up to 15 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of EBT-101</measure>
    <time_frame>48 weeks</time_frame>
    <description>Safety and tolerability of EBT-101 will be assessed based on the incidence and severity of adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 48 weeks</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>EBT-101 Dose-Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: Participants will be administered dose-level 1 of EBT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBT-101 Dose-Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B: Participants will be administered dose-level 2 of EBT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBT-101 Dose-Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C: Participants will be administered dose-level 3 of EBT-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EBT-101</intervention_name>
    <description>EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration</description>
    <arm_group_label>EBT-101 Dose-Level 1</arm_group_label>
    <arm_group_label>EBT-101 Dose-Level 2</arm_group_label>
    <arm_group_label>EBT-101 Dose-Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated):&#xD;
&#xD;
          -  Participants 18 to 60 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Documented chronic HIV-1 infection on stable ART regimen&#xD;
&#xD;
          -  Plasma HIV-1 levels below the limit of quantification&#xD;
&#xD;
          -  Peripheral blood cluster of differentiation 4 (CD4) T cell count &gt;500 cells/mm3 during&#xD;
             screening&#xD;
&#xD;
          -  Have previously been vaccinated for N. meningitidis with documented history and/or&#xD;
             received a N. meningitidis vaccination prior to dosing&#xD;
&#xD;
          -  Must be willing to use condoms throughout the duration of the study&#xD;
&#xD;
          -  Willing to enroll into the Long-Term Follow-Up Study, EBT-101-002, for up to 15 years&#xD;
             after receiving study drug&#xD;
&#xD;
        Exclusion Criteria (abbreviated):&#xD;
&#xD;
          -  Anti-AAV9 serum neutralizing antibodies &gt;1:20 titer&#xD;
&#xD;
          -  History of one or more HIV-related opportunistic infections within the past 2 years&#xD;
&#xD;
          -  Documented prior HIV-1 drug resistance to â‰¥2 or more classes of ART defined as a&#xD;
             single key mutations or an accumulation of minor mutations that result in resistance&#xD;
             to entire respective drug classes within the past 5 years&#xD;
&#xD;
          -  History of &gt;1 change in ART due to virologic failure during preceding 2 years.&#xD;
&#xD;
          -  Receiving or plans to receive long-acting injectable ART&#xD;
&#xD;
          -  History of malignancy with the exception of successfully treated basal cell or&#xD;
             squamous cell carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cohort A will enroll male adults (sex at birth)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Excision BioTherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director at ExcisionBio</last_name>
    <phone>833-214-2241</phone>
    <email>clinicalscience@excisionbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Lead at ExcisionBio</last_name>
    <email>clinicalscience@excisionbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRISPR</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>AAV9</keyword>
  <keyword>HIV</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

